BLA 761177 · Ascendis Pharma Encocrinology Div A/S
Skytrofa
Lonapegsomatropin-Tcgd · Injection · Recombinant Human Growth Hormone
NovelOrphanCDER novel approval, Aug 25, 2021: To treat short stature due to inadequate secretion of endogenous growth hormone
Last checked: Nov 20, 2026Latest source record: Jul 25, 2025 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2021
Aug 25, 2021
Approved uses
n/a
Original approval plus efficacy supplements
Registered trials
6
4 Phase 3, 1 recruiting
FAERS reports
0
0 serious, 0 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
No structured label for this application in openFDA. FDA's summary: To treat short stature due to inadequate secretion of endogenous growth hormone
Therapeutic areas: Endocrinology and women's health
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
No approvals could be loaded from Drugs@FDA just now.
Clinical trials
Interventional ClinicalTrials.gov studies with "Lonapegsomatropin" as an intervention, any sponsor and status, largest first.
- A Trial to Compare the Efficacy and Safety of Once-weekly Lonapegsomatropin With Placebo and a Daily Somatropin Product in Adults With Growth Hormone DeficiencyPivotal-lookingCompleted
Ascendis Pharma Endocrinology Division A/SIndustry
NCT04615273 · 264 participants · Start Dec 3, 2020 · Primary completion Nov 2, 2023
Drug: Lonapegsomatropin; Somatropin · For: Growth Hormone Deficiency; Endocrine System Diseases; Hormone Deficiency
Sites: Birmingham, Alabama; Phoenix, Arizona; Fresno, California · 113 sites in all
- A Trial to Investigate Long Term Efficacy and Safety of Lonapegsomatropin in Adults With Growth Hormone DeficiencyPivotal-lookingCompleted
Ascendis Pharma Endocrinology Division A/SIndustry
NCT05171855 · 220 participants · Start Dec 16, 2021 · Primary completion Dec 23, 2024
Drug: Lonapegsomatropin · For: Adult Growth Hormone Deficiency; Endocrine System Diseases; Hormone Deficiency
Sites: Phoenix, Arizona; Torrance, California; Chicago, Illinois · 85 sites in all
- Safety, Tolerability and Efficacy of TransCon hGH Weekly Versus Daily hGH in Chinese Pediatric Growth Hormone DeficiencyPivotal-lookingStatus unknown
Visen Pharmaceuticals (Shanghai) Co., Ltd.Industry
NCT04326374 · 150 participants (planned) · Start Dec 30, 2019 · Primary completion Apr 2022
Drug: TransCon hGH; daily hGH · For: Growth Hormone Deficiency; Endocrine System Diseases; Hormones and 2 more
Sites: Wuhan, China
- Clinical Trial Evaluating the Efficacy and Safety of Navepegritide and Lonapegsomatropin in AchondroplasiaPivotal-lookingNot yet recruiting
Ascendis Pharma A/SIndustry
NCT07924059 · 144 participants (planned) · Start Nov 2026 · Primary completion Sep 2028
Drug: Dual therapy with navepegritide and lonapegsomatropin; Dual therapy with navepegritide and placebo for lonapegsomatropin and 1 more · For: Achondroplasia
- A Trial to Investigate Different Doses of Lonapegsomatropin Compared to Somatropin in Individuals With Turner SyndromeActive, not recruiting
Ascendis Pharma Endocrinology Division A/SIndustry
NCT05690386 · 48 participants · Start Feb 15, 2023 · Primary completion Oct 18, 2024
Drug: Lonapegsomatropin; Somatropin · For: Turner Syndrome
Sites: Palo Alto, California; San Diego, California; Aurora, Colorado · 19 sites in all
- A Phase 2 Clinical Trial to Evaluate Efficacy, Safety, and Tolerability of Navepegritide in Combination With Lonapegsomatropin in Children With AchondroplasiaActive, not recruiting
Ascendis Pharma Growth Disorders A/SIndustry
NCT06433557 · 22 participants · Start Jul 26, 2024 · Primary completion Nov 14, 2025
Drug: Combination of Navepegritide and Lonapegsomatropin administered as two separate s.c. injections · For: Achondroplasia
Sites: Copenhagen, Denmark; Dublin, Ireland; London, United Kingdom
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
No FAERS reports name this application.
FAERS reports by year
By the date FDA received the report.
No reports.
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Skytrofa (Lonapegsomatropin-Tcgd)
2024 spending
$159K
Beneficiaries
n/a
21 claims
Per beneficiary
n/a
$1,802.83 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $0 |
| 2021 | $0 |
| 2022 | $0 |
| 2023 | $0 |
| 2024 | $158,521 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Weekly Lonapegsomatropin in Treatment-Naïve Children With Growth Hormone Deficiency: The Phase 3 heiGHt Trial.
Thornton PS, Maniatis AK, Aghajanova E, et al. · J Clin Endocrinol Metab 2021 · Clinical Trial, Phase III, Randomized Controlled Trial
- Efficacy and Safety of Somapacitan Relative to Somatrogon and Lonapegsomatropin in Pediatric Growth Hormone Deficiency: Systematic Literature Review and Network Meta-analysis.
de Fries Jensen L, Antavalis V, Odgaard-Jensen J, et al. · Adv Ther 2024 · Comparative Study, Systematic Review
- Children with Growth Hormone Deficiency Treated with Lonapegsomatropin Demonstrated Sustained Height Improvements for up to 6 Years: enliGHten Trial Final Results.
Maniatis AK, Thornton PS, Nadgir UM, et al. · Horm Res Paediatr 2026 · Multicenter Study, Clinical Trial, Phase III
- Safety and Efficacy of Lonapegsomatropin in Children With Growth Hormone Deficiency: enliGHten Trial 2-Year Results.
Maniatis AK, Casella SJ, Nadgir UM, et al. · J Clin Endocrinol Metab 2022 · Clinical Trial, Phase III, Research Support, Non-U.S. Gov't
- Efficacy and Safety of Once-Weekly Lonapegsomatropin in Adults With Growth Hormone Deficiency: foresiGHt Trial Results.
Biller BMK, Gilis-Januszewska A, Doknic M, et al. · J Clin Endocrinol Metab 2026 · Randomized Controlled Trial, Multicenter Study
- Switching to Weekly Lonapegsomatropin from Daily Somatropin in Children with Growth Hormone Deficiency: The fliGHt Trial.
Maniatis AK, Nadgir U, Saenger P, et al. · Horm Res Paediatr 2022 · Clinical Trial, Phase III, Multicenter Study
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.